ABSTRACT
BACKGROUND Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD).
OBJECTIVE To identify how value assessment frameworks may need to be adapted to measure the value to society of DMD therapies.
METHODS Three groups of stakeholders (patient advocates, clinicians, health economists) participated in semi-structured interviews around the International Society for Pharmacoeconomics and Outcomes Research’s Value Flower, which includes elements of value that can be considered within value assessments of healthcare technologies.
RESULTS All stakeholders agreed that traditional value assessment frameworks based on the quality-adjusted life year (QALY) are narrow and will undervalue new DMD therapies. All stakeholders expressed some level of concern that use of the QALY as a key metric of value discriminates against patients with severe progressive diseases and disabilities. Some stakeholders saw value in using the QALY for cross-disease comparisons in resource-constrained environments if the methodology was appropriate. All stakeholders recommended considering additional elements of value in decision-making around new DMD therapies. These elements reflect: the economic and humanistic costs incurred by patients, caregivers, and families with Duchenne, such as indirect out-of-pocket costs, lost productivity, and family spillovers; the attributes that are meaningful for individuals with disabilities and high unmet need, such as severity of disease, value of hope, and real option value; and factors that contribute to improvements in population health, such as insurance value, equity, and scientific spillovers.
CONCLUSIONS These findings highlight the need to expand traditional value assessment frameworks and take a holistic approach that incorporates the perspectives of individuals with Duchenne, caregivers, clinicians, and heath economists when assessing the societal value of new DMD therapies. Broadening value assessment will prevent restricted or delayed access to therapies for individuals with Duchenne.
Competing Interest Statement
RF, PF, AK, KM, MP, and DM have no conflict of interest to report. CGL serves on advisory boards/consults with Avidity, Roche, Novartis, and Sarepta Therapeutics. LL provides training for Sarepta Therapeutics. NLK serves on advisory boards/consults with Astellas, Argenx, Biogen, Novartis, Roche, and Sarepta Therapeutics. PBS has served as a consultant to Novartis Gene Therapies, Biogen, Genentech, Sarepta Therapeutics, Pfizer, Solid Biosciences, Astellas Gene Therapies, Argenx, Alexion, Catalyst Pharma, Grifols, and CSL Behring. JK is an employee of SNELL Medical Communication, Inc., which has received funding from Sarepta Therapeutics. PJN has consulted and participated on advisory boards for Sarepta Therapeutics. JS is an employee of FTI Consulting, a consulting firm to healthcare, life sciences, and other industries. RJW served as a consultant to Sarepta Therapeutics in the work leading to the creation of this manuscript and has served on advisory boards and as a consultant on projects sponsored by several other biopharmaceutical companies.
Funding Statement
Funding for this paper was provided by Sarepta Therapeutics, Inc. Medical writing and editorial support were funded by Sarepta Therapeutics, Inc. The authors retained editorial control.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during this study.
